Alzheimer's drug, Eli Lilly's donanemab, can slow disease by a few months, with risks, study finds - CBS News

Similar to Leqembi, the Eli Lilly drug is designed to target and clear away a sticky protein called beta-amyloid that builds up into brain-clogging plaques that are one hallmark of Alzheimer's. Read More

Alzheimer's drug donanemab, by Eli Lilly, slows decline, study finds. - USA TODAY

A new study reports Eli Lilly's Alzheimer's drug slowed cognitive and functional decline for people with early stages of the disease. The data, published Monday in the Journal of the American ... Read More

FDA approves Eli Lilly's Alzheimer’s drug that slows memory decline - NBC News

Eli Lilly. The agency’s approval was based on a late-stage clinical trial of 1,700 people that showed the drug slowed the progression of Alzheimer’s by about 35% after 18 months, compared to a ... Read More

Eli Lilly Stock Is Falling. It Isn’t Just About Tariffs.

Lilly shares were down 2.9% Monday, and Novo’s American depositary receipts were up 1.8%, as worries over tariffs unsettled the market. The S&P 500 was roughly flat after a series of dramatic ... Read More

Eli Lilly Downplays CVS Move to Drop Zepbound Coverage, Shares Plunge - U.S. News & World Report

(Reuters) -Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of medicines it covers for reimbursement, but shares of the drugmaker ... Read More

Eli Lilly Surpasses UnitedHealth as World’s Biggest Health-Care Firm

Eli Lilly & Co. became the world’s biggest health-care company by market value, surging ahead of health insurance giant UnitedHealth Group Inc. The drugmaker gained 0.9% on Wednesday, extending ... Read More

Eli Lilly downplays CVS move to drop Zepbound coverage, shares plunge - Yahoo Finance

(Reuters) -Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of medicines it covers for reimbursement, but shares of the drugmaker ... Read More

Eli Lilly says Alzheimer’s drug approval delayed as FDA seeks input from advisers - CNN

Drugmaker Eli Lilly says that approval of its experimental Alzheimer’s medication donanemab will be delayed beyond the end of March as the US Food and Drug Administration plans to call a last ... Read More

Former Lilly executives donate $20 million for IU clinical institute - IndyStar

Two former Eli Lilly executives and their families will donate $20 million to IU Health Foundation — the largest philanthropic gift in the foundation's history — to establish the Institute for ... Read More

FDA panel backs Eli Lilly's Alzheimer's drug donanemab

The Food and Drug Administration’s (FDA) Peripheral and Central Nervous System Drugs Advisory Committee met Monday to discuss Eli Lilly’s donanemab. The committee’s voting members were… ... Read More

Eli Lilly sues telehealth companies selling compounded Zepbound, Mounjaro

Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its diabetes treatment Mounjaro, escalating its battle against unauthorized ... Read More